bioRxivBiochemistryPreprint
Coupling high-throughput protease enzymology with viral replication reveals biochemical constraints of viral fitness
Dylan Aidlen, William Vinh Thanh Vo, Nicholas J. YoungiD, Julia RosecransiD, Anna Kurianowicz, Shih‐Wei ChuoiD, Garrison P. R. AsperiD, Dashiell Anderson, Jacob A. PosneriD, Duncan F. MuiriD, Nicholas Freitas, Mélanie OttiD, Charles S. CraikiD, Taha Y. TahaiD, Margaux M. PinneyiD
Abstract
Proteases govern essential biological processes and are key drug targets, yet how protease sequence variation quantitatively reshapes biochemical parameters and constrains biological fitness remains poorly understood. Here, we integrate high-throughput in vitro enzymology with cellular assays to link protease sequence, biochemistry, and fitness. We extend a microfluidic platform for high-throughput protease enzymology (HT-MEKpro), which is broadly applicable across protease families and catalytic classes, enabling measurement of catalytic turnover (kcat), Michaelis constant (KM), inhibitor potency (IC50), and relative substrate specificity for 102-103 variants. Applied to the SARS-CoV-2 main protease (Mpro), HT-MEKpro generated parallel catalytic and inhibitory landscapes for >400 variants. Integration with viral replication and in-cell cleavage assays reveals that variants with altered substrate specificity fail to support replication, suggesting imbalanced polyprotein processing as a constraint on viral fitness. More broadly, these data can enable mechanistically grounded modeling of protease sequence-property relationships and inform strategies for pharmacological modulation beyond active-site inhibition.
- organism: virus
- assay: proteomics
- research focus: drug response / drug discovery
- approach: experimental assay
- Citations
- 2
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Functional Characterization of SARS-CoV-2 3CLpro Variants
Dipon Saha, S. Yasin Tabatabaei Dakhili, … Dieter Brömme·bioRxiv·Sep 10, 2026
- Sequence Characterization and Molecular Modeling of Clinically Relevant Variants of the SARS-CoV-2 Main Protease
Thomas J. Cross, Gemma R. Takahashi, … Rachel W. Martin·BiochemistryPeer-reviewed·Sep 15, 2020
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19
K. Steuten, H. Kim, … M. Bogyo·bioRxiv·Nov 21, 2020
- SARS-CoV-2 Mpro protease variants of concern display altered viral and host target processing but retain potency towards antivirals
S. A. Chen, E. Arutyunova, … M. J. Lemieux·bioRxiv·Jan 28, 2023
- Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
J. Osipiuk, Saara‐Anne Azizi, … A. Joachimiak·Nature CommunicationsPeer-reviewed·Feb 2, 2021
- Structural Differences In 3C-like protease (Mpro) From SARS-CoV and SARS-CoV-2: Molecular Insights For Drug Repurposing Against COVID-19 Revealed by Molecular Dynamics Simulations.
Meet Parmar, Ritik Thumar, … Dhaval Patel·bioRxiv·Aug 11, 2021